Advice
following an abbreviated submission:
sevelamer carbonate (Renvela®) is accepted for restricted use within NHS Scotland.
Indication under review: control of hyperphosphataemia in paediatric patients (>6 years of age and a Body Surface Area of >0.75m2) with chronic kidney disease.
SMC restriction: the second-line management of hyperphosphataemia in patients receiving haemodialysis.
SMC has previously accepted sevelamer carbonate for restricted use in the second-line management of hyperphosphataemia in adult patients receiving haemodialysis.
Download detailed advice45KB (PDF)
Medicine details
- Medicine name:
- sevelamer carbonate (Renvela)
- SMC ID:
- 1304/18
- Indication:
- Control of hyperphosphataemia in paediatric patients (>6 years of age and a Body Surface Area of >0.75m2) with chronic kidney disease.
- Pharmaceutical company
- Sanofi
- BNF chapter
- Nutrition and blood
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 12 February 2018